Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284828 | 1.00 | KMT2A (0.46) | KMT2ASMN1; SMN2SLC7A5ANPEPCA2 | |
| SCHEMBL2765505 | 1.00 | KMT2A (0.46) | KMT2ASMN1; SMN2SLC7A5ANPEPCA2 | |
| Bicarbonate SCHEMBL15743197 | 0.98 | KMT2A (0.45) | KMT2ASMN1; SMN2SLC7A5ANPEPCA2 | |
| SCHEMBL8407301 | 0.83 | CA2 (0.47) | SLC7A5ANPEPCA2CYP2C9CYP2D6 | |
| SCHEMBL27735171 | 0.83 | CA2 (0.47) | SLC7A5ANPEPCA2CYP2C9CYP2D6 | |
| SCHEMBL2303463 | 0.83 | SMN1; SMN2 (0.54) | KMT2ASMN1; SMN2ANPEPCYP2C9MEN1 | |
| SCHEMBL7104404 | 0.83 | SMN1; SMN2 (0.54) | KMT2ASMN1; SMN2ANPEPCYP2C9MEN1 | |
| SCHEMBL59840 | 0.83 | GABBR2 (0.59) | KMT2ASMN1; SMN2CYP2D6CYP2C19GABBR2 | |
| SCHEMBL288753 | 0.83 | GABBR2 (0.59) | KMT2ASMN1; SMN2CYP2D6CYP2C19GABBR2 | |
| SCHEMBL123765 | 0.83 | GABBR2 (0.59) | KMT2ASMN1; SMN2CYP2D6CYP2C19GABBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101678118-A | Efficient synthesis of chelators for nuclear imaging and radiotherapy: composition and use | UNIV TEXAS | 2010-03-24 | — | — | CN | claimed |
| CN-101516899-A | Compositions and methods for cellular imaging and therapy | UNIV TEXAS (US) | 2009-08-26 | — | — | CN | claimed |
| CN-119074710-A | Use of l-tyrosine in medicaments for the treatment of obsessive-compulsive disorders | 重庆医科大学 | 2024-12-06 | — | — | CN | disclosed |
| CN-114728965-B | Pyrido heterocyclic compounds, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| US-11702652-B2 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION A/S (DK) | 2023-07-18 | — | — | US | disclosed |
| CN-116240157-A | Directional transformation method of L-tyrosine efficient production strain and production strain | 天津科技大学 | 2023-06-09 | — | — | CN | disclosed |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| CN-114728965-A | Pyridino-heterocyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3305900-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| US-20080255095-A1 | Benzylamine analogues | BTG INTERNATIONAL LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008030618-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| EP-1362844-B1 | BENZYLAMINE ANALOGUE | BTG INT LTD (GB) | 2007-12-05 | — | — | EP | disclosed |
| WO-2007062664-A2 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION A/S (DK) | 2007-06-07 | — | — | WO | disclosed |
| US-20070037795-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | BTG INTERNATIONAL LIMITED (GB) | 2007-02-15 | — | — | US | disclosed |
| US-20070037793-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | BTG INTERNATIONAL LIMITED (GB) | 2007-02-15 | — | — | US | disclosed |
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | SANKYO COMPANY, LIMITED (JP) | 2004-04-08 | — | — | US | disclosed |
| EP-1362844-A1 | BENZYLAMINE ANALOGUE | Sankyo Company, Limited (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | KMT2A 4739/4885SMN1; SMN2 4722/4885SLC7A5 2832/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | KMT2A 4739/4885SMN1; SMN2 4722/4885SLC7A5 2832/4885 |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | KMT2A 1619/4885SMN1; SMN2 3293/4885SLC7A5 2100/4885 |
| US-20070037793-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | CHRNA4, SLC6A4, DRD4 | KMT2A 1565/4885SMN1; SMN2 1114/4885SLC7A5 417/4885 |
| US-20070037795-A1 | 2-methyl-1-[2-(4-nitrophenoxy)-ethyl]-1,2,3,4-tetrahydroisoquinolin-6-yl dimethylcarbamate; Acetylcholinesterase inhibitors; selective serotonin reuptake inhibitory; Alzheimer's disease, depression, Huntington's chorea, Pick's disease, tardive dyskinesia, compulsive disorders or panic disorders | SLC6A4, SLC6A3, HTR4 | KMT2A 2146/4885SMN1; SMN2 834/4885SLC7A5 368/4885 |
| US-20040067981-A1 | Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants | ACHE, BACE1, CHRNA6 | KMT2A 1769/4885SMN1; SMN2 725/4885SLC7A5 800/4885 |
| US-20080255095-A1 | Benzylamine analogues | NR4A3, NAT1, HRH4 | KMT2A 2769/4885SMN1; SMN2 2333/4885SLC7A5 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.